PTC Therapeutics' Phase II trial of utreloxastat for ALS did not meet primary endpoints, leading to trial termination. Despite some modest benefits, the drug showed no statistical improvement, resulting in its discontinuation. The company will no longer pursue the product due to lack of efficacy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing